Haemophilia B News and Research

RSS
Baxter submits BAX 855 NDA to Japan's MHLW for treatment of hemophilia A patients

Baxter submits BAX 855 NDA to Japan's MHLW for treatment of hemophilia A patients

Added benefit of simoctocog alfa not proven for haemophilia A

Added benefit of simoctocog alfa not proven for haemophilia A

Novo Nordisk reports positive data from Novoeight phase 3 study in people with haemophilia A

Novo Nordisk reports positive data from Novoeight phase 3 study in people with haemophilia A

Researchers set up innovative project to monitor physical activity of patients with haemophilia

Researchers set up innovative project to monitor physical activity of patients with haemophilia

Apitope's ATX-F8-117 granted orphan medicinal product designation for treatment of haemophilia A

Apitope's ATX-F8-117 granted orphan medicinal product designation for treatment of haemophilia A

EMA recommends marketing authorisation for Octapharma’s human cell line recombinant human FVIII, Nuwiq

EMA recommends marketing authorisation for Octapharma’s human cell line recombinant human FVIII, Nuwiq

Study: Added benefit of turoctocog alfa is not proven

Study: Added benefit of turoctocog alfa is not proven

OPKO Health consolidated revenues increase about 30% to $20.7 million in Q4 2013

OPKO Health consolidated revenues increase about 30% to $20.7 million in Q4 2013

Novo Nordisk to use Trialbee's services for e-recruitment of patients for clinical studies

Novo Nordisk to use Trialbee's services for e-recruitment of patients for clinical studies

Alnylam presents new pre-clinical data with ALN-AT3 for treatment of hemophilia and RBD

Alnylam presents new pre-clinical data with ALN-AT3 for treatment of hemophilia and RBD

Biogen, Sobi present new data supporting clinical, safety profile of ELOCTATE for hemophilia A

Biogen, Sobi present new data supporting clinical, safety profile of ELOCTATE for hemophilia A

Biogen, Sobi present new findings from Phase 3 trial of ALPROLIX at XXIV ISTH Congress

Biogen, Sobi present new findings from Phase 3 trial of ALPROLIX at XXIV ISTH Congress

Alnylam Pharmaceuticals presents new pre-clinical data of ALN-AT3 at ISTH meeting

Alnylam Pharmaceuticals presents new pre-clinical data of ALN-AT3 at ISTH meeting

Study sheds light on stem cell technique for treatment of common bleeding disorder

Study sheds light on stem cell technique for treatment of common bleeding disorder

Biogen Idec, Sobi release data from rFVIIIFc and rFIXFc phase 3 trials on hemophilia

Biogen Idec, Sobi release data from rFVIIIFc and rFIXFc phase 3 trials on hemophilia

Researchers to develop new diagnostic tools and treatments for people with rare diseases

Researchers to develop new diagnostic tools and treatments for people with rare diseases

Interim results from Inspiration’s OBI-1 and IB1001 hemophilia clinical study

Interim results from Inspiration’s OBI-1 and IB1001 hemophilia clinical study

Hemostatic testing may explain heavy menstrual bleeding

Hemostatic testing may explain heavy menstrual bleeding

European collaboration to design a biomimetic bioartificial liver

European collaboration to design a biomimetic bioartificial liver

Study describes new method that synthesizes novel anti-HIV protein

Study describes new method that synthesizes novel anti-HIV protein